Cargando…

Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma

BACKGROUND: Primary adenosquamous carcinoma (ASC) of the lung is a rare and aggressive disease and limited information is available on the efficacy of immune checkpoint inhibitors (ICIs) for this disease. Here, we evaluated the expression status of programmed death-1 ligand 1 (PD-L1) and efﬁcacy of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Jingwen, Xiang, Jing, Hao, Yue, Si, Jinfei, Gu, Xiaodong, Xu, Manyi, Song, Zhengbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992578/ https://www.ncbi.nlm.nih.gov/pubmed/36910045 http://dx.doi.org/10.21037/jtd-22-1011

Ejemplares similares

Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer
por: Xu, Manyi, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma
por: Shi, Zheng, et al.
Publicado: (2023)

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
por: Si, Jinfei, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study
por: Xiang, Jing, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
por: Gu, Xiaodong, et al.
Publicado: (2023)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
por: Hao, Yue, et al.
Publicado: (2023)

Adenosquamous carcinoma of the lung
por: Li, Chenghui, et al.
Publicado: (2018)

Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma
por: Hao, Yue, et al.
Publicado: (2022)

Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study
por: Wei, Jingwen, et al.
Publicado: (2022)

Clonal Analysis of Adenosquamous Carcinoma of the Lung
por: Niho, Seiji, et al.
Publicado: (1999)

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study
por: Gu, Xiaodong, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Research progress of the clinicopathologic features of lung adenosquamous carcinoma
por: Wang, Jing, et al.
Publicado: (2018)

The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
por: Guan, Yelan, et al.
Publicado: (2023)

Survival analysis for lung adenosquamous carcinoma patients with brain metastasis
por: Pan, Feng, et al.
Publicado: (2018)

Adenosquamous carcinoma of the liver
por: Park, Shin Young, et al.
Publicado: (2012)

Adenosquamous Carcinoma of the Colon
por: Sunkara, Tagore, et al.
Publicado: (2018)

Adenosquamous Carcinoma of the Choledochus
por: Uehara, Daisuke, et al.
Publicado: (2019)

Adenosquamous Carcinoma of the Pancreas
por: Del Arco, Hélène, et al.
Publicado: (2019)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

A case of primary adenosquamous carcinoma of the liver
por: Kang, Gu Hyum, et al.
Publicado: (2013)

Primary renal adenosquamous carcinoma
por: Zainuddin, Mohammad Ashik, et al.
Publicado: (2010)

Primary adenosquamous carcinoma of the colon
por: Kang, Dong Baek, et al.
Publicado: (2011)

Adenosquamous carcinoma of the parotid gland
por: Kusafuka, Kimihide, et al.
Publicado: (2013)

Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?
por: Vassella, Erik, et al.
Publicado: (2015)

Development of an adenosquamous carcinoma histopathology – selective lung metastasis model
por: Lähdeniemi, Iris A. K., et al.
Publicado: (2022)

Hypercalcemia-Leukocytosis syndrome and adenosquamous lung carcinoma: An overlooked conjugation
por: OLIVEIRA PEREIRA, JOÃO, et al.
Publicado: (2022)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection
por: Fan, Liwen, et al.
Publicado: (2017)

The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Jingwen, et al.
Publicado: (2021)

Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma
por: Lee, Ahlim, et al.
Publicado: (2022)

Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma
por: Li, Chao, et al.
Publicado: (2022)

The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
por: Yu, Xiaoqing, et al.
Publicado: (2022)

Metastatic gallbladder adenosquamous carcinoma to the skin(†)
por: Lupinacci, Renato Micelli, et al.
Publicado: (2014)

Prostatic Adenosquamous Carcinoma Metastasizing to Testis
por: Baydar, Dilek Ertoy, et al.
Publicado: (2006)

Adenosquamous Carcinoma of the Gallbladder With Sarcomatoid Features
por: Majeed, Nasma K., et al.
Publicado: (2020)

Adenosquamous Carcinoma of the Extrahepatic Bile Duct
por: Gupta, Deepika, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
por: Hung, Hao-Chien, et al.
Publicado: (2021)

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
por: Wang, Chengdi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ns1j9tdd5injqn8doqvse0khvl